文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

Adrecizumab(HAM8101)在脓毒性休克患者中的安全性与耐受性:AdrenOSS-2 2a期生物标志物引导试验

Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.
PubMed 文献 · Intensive Care Med · 2021-10-04
一句话结论在肾上腺素髓质素>70 pg/mL的脓毒性休克患者中,单次输注adrecizumab 2或4 mg/kg未显示明显伤害信号,但疗效未证实。

AdrenOSS-2是一项2a期、双盲、随机、安慰剂对照、生物标志物引导试验,纳入301例肾上腺素髓质素>70 pg/mL、血管升压药启动<12 h的脓毒性休克患者,按1:1:2随机接受单次adrecizumab 2或4 mg/kg或安慰剂。主要安全终点(90天死亡率、TEAE)和耐受性终点(药物中断、血流动力学)无组间差异;TEAE≥3级在adrecizumab组70.5%、安慰剂组71.1%。SSI变化差异0.72(CI -1.93-0.49,p=0.24),28天死亡率23.9% vs 27.7%(HR 0.84,95%CI 0.53-1.31,p=0.44);delta SOFA在adrecizumab合并组较安慰剂更明显(差异0.76,95%CI 0.18-1.35,p=0.007)。结论:未发现明显伤害信号,但需进一步RCT确认疗效与安全性。

要点

  • 适用人群:脓毒性休克、肾上腺素髓质素>70 pg/mL、血管升压药启动<12 h者;单次输注adrecizumab 2或4 mg/kg。
  • 安全性:TEAE≥3级adrecizumab组70.5% vs 安慰剂组71.1%,90天死亡率无组间差异;仅1例药物中断,无血流动力学改变。
  • 主要疗效终点SSI变化差异0.72(CI -1.93-0.49,p=0.24),28天死亡率23.9% vs 27.7%(HR 0.84,95%CI 0.53-1.31,p=0.44),均未达统计学显著。
  • 次要终点delta SOFA在adrecizumab合并组较安慰剂更明显(差异0.76,95%CI 0.18-1.35,p=0.007)。
  • 结论:未发现明显伤害信号,但疗效未证实,需进一步RCT确认。

适用人群与场景

  • 纳入:脓毒性休克患者,肾上腺素髓质素>70 pg/mL,血管升压药启动<12 h;随机化时中位血管升压药启动后8.5 h。
  • 排除人群:原文未提及。
  • 场景:急诊/ICU脓毒性休克早期(血管升压药启动<12 h)。

诊断标准与关键阈值

  • 入选标准:脓毒性休克且肾上腺素髓质素>70 pg/mL,血管升压药启动<12 h。
  • 生物标志物引导:以肾上腺素髓质素>70 pg/mL筛选患者。

处置流程与药物剂量

  • 第一步:筛选脓毒性休克患者,检测肾上腺素髓质素,>70 pg/mL且血管升压药启动<12 h者符合入选。
  • 第二步:按1:1:2随机分配至adrecizumab 2 mg/kg、4 mg/kg或安慰剂组。
  • 第三步:单次静脉输注adrecizumab(2或4 mg/kg b.w.)或安慰剂。
  • 第四步:记录主要安全终点(90天死亡率、TEAE)和耐受性终点(药物中断、血流动力学)。
  • 第五步:评估疗效终点,包括SSI、SOFA变化和28天死亡率。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:2a期、双盲、随机、安慰剂对照、生物标志物引导试验;样本量301例;中心数原文未提及。
  • 人群:脓毒性休克、肾上腺素髓质素>70 pg/mL、血管升压药启动<12 h;随机化时中位血管升压药启动后8.5 h。
  • 干预与对照:单次输注adrecizumab 2或4 mg/kg vs 安慰剂,随机1:1:2。
  • 主要安全终点:TEAE≥3级adrecizumab组70.5% vs 安慰剂组71.1%;90天死亡率无组间差异;仅1例药物中断,无血流动力学改变。
  • 主要疗效终点:SSI变化差异0.72(CI -1.93-0.49,p=0.24)。
  • 关键次要终点:delta SOFA在adrecizumab合并组较安慰剂更明显(差异0.76,95%CI 0.18-1.35,p=0.007);28天死亡率23.9% vs 27.7%(HR 0.84,95%CI 0.53-1.31,log-rank p=0.44)。
  • 不良事件:TEAE频率和严重程度组间无差异。

证据类型、等级与局限

  • 证据类型:2a期随机对照试验(RCT)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:2a期试验,样本量301例,单次输注,疗效未达主要终点,需进一步RCT确认疗效与安全性;中心数、盲法实施细节原文未提及。

对床旁实践的改变

  • 在脓毒性休克且肾上腺素髓质素>70 pg/mL、血管升压药启动<12 h的患者中,单次adrecizumab 2或4 mg/kg未显示明显伤害信号,但疗效未证实,不能据此改变常规实践。
  • delta SOFA在adrecizumab合并组更明显(p=0.007)为次要终点,需进一步RCT验证,不能作为床旁决策依据。
  • 生物标志物引导筛选(肾上腺素髓质素>70 pg/mL)可用于未来试验设计,但当前不推荐常规使用adrecizumab。

指南或共识出处

  • AdrenOSS-2 2a期生物标志物引导试验(Intensive Care Med),原文未提供指南或共识名称。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

PURPOSE: Investigate safety and tolerability of adrecizumab, a humanized monoclonal adrenomedullin antibody, in septic shock patients with high adrenomedullin.

METHODS: Phase-2a, double-blind, randomized, placebo-controlled biomarker-guided trial with a single infusion of adrecizumab (2 or 4 mg/kg b.w.) compared to placebo. Patients with adrenomedullin above 70 pg/mL, < 12 h of vasopressor start for septic shock were eligible. Randomization was 1:1:2. Primary safety (90-day mortality, treatment emergent adverse events (TEAE)) and tolerability (drug interruption, hemodynamics) endpoints were recorded. Efficacy endpoints included the Sepsis Support Index (SSI, reflecting ventilator- and shock-free days alive), change in Sequential-related Organ Failure Assessment (SOFA) and 28-day mortality.

RESULTS: 301 patients were enrolled (median time of 8.5 h after vasopressor start). Adrecizumab was well tolerated (one interruption, no hemodynamic alteration) with no differences in frequency and severity in TEAEs between treatment arms (TEAE of grade 3 or higher: 70.5% in the adrecizumab group and 71.1% in the placebo group) nor in 90-day mortality. Difference in change in SSI between adrecizumab and placebo was 0.72 (CI -1.93-0.49, p = 0.24). Among various secondary endpoints, delta SOFA score (defined as maximum versus minimum SOFA) was more pronounced in the adrecizumab combined group compared to placebo [difference at 0.76 (95% CI 0.18-1.35); p = 0.007]. 28-day mortality in the adrecizumab group was 23.9% and 27.7% in placebo with a hazard ratio of 0.84 (95% confidence interval 0.53-1.31, log-rank p = 0.44).

CONCLUSIONS: Overall, we successfully completed a randomized trial evaluating selecting patients for enrolment who had a disease-related biomarker. There were no overt signals of harm with using two doses of the adrenomedullin antibody adrecizumab; however, further randomized controlled trials are required to confirm efficacy and safety of this agent in septic shock patients.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Laterre PF, Pickkers P, Marx G, et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Med. 2021. PMID: 34605947. doi:10.1007/s00134-021-06537-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。